Polycystic ovary syndrome affects 8–13% of reproductive-age women. Insulin resistance is central to its pathophysiology. GLP-1 receptor agonists — by improving insulin sensitivity and reducing weight — address the metabolic core of PCOS, and emerging evidence shows clinical benefit on cycle regularity, ovulation, and metabolic markers.
Why GLP-1 makes sense in PCOS
PCOS is characterized by:
- Insulin resistance — present in 70–80% of PCOS patients regardless of weight.
- Hyperandrogenism — driven in part by insulin's stimulation of ovarian androgen production.
- Anovulation — driven by disordered GnRH pulsatility and elevated insulin/IGF-1.
- Long-term metabolic risk — elevated T2D, CVD, MASLD risk.
GLP-1 receptor agonists improve insulin sensitivity, reduce body weight, and (downstream) reduce ovarian androgen production. The mechanism aligns directly with PCOS pathophysiology.
The evidence — small but consistent
PCOS-specific phase 3 trial data are limited but accumulating. Several smaller randomized trials and observational cohorts show:
- Weight reduction comparable to non-PCOS obesity populations (10–20% with semaglutide; higher with tirzepatide).
- Cycle regularization in a meaningful proportion of patients with prior anovulation.
- Restoration of ovulation in patients with weight-related anovulation.
- Reductions in fasting insulin, HOMA-IR, and total testosterone.
Larger trials (PCOS-specific phase 3 programs) are not yet running, but the off-label use is common and supported by mechanism.
The fertility consideration
This is the most consequential clinical issue. GLP-1 therapy frequently restores ovulation in patients with weight-related anovulation — including patients who had been previously infertile. The combination of "I started GLP-1 therapy and unexpectedly conceived" is well documented in PCOS practice.
Practical implications:
- If pregnancy is desired: GLP-1 may be an effective ovulation-induction adjunct, but should be stopped ≥2 months (semaglutide) or ≥1 month (tirzepatide) before attempting conception.
- If pregnancy is not desired: reliable contraception is essential throughout treatment. Patients who had assumed they could not conceive due to long-standing infertility need this discussion.
Hirsutism and androgen effects
Improvements in hirsutism on GLP-1 therapy are typically modest and slow. The dominant driver is reduction in fasting insulin → reduced ovarian androgen production. Patients with significant hirsutism does not expect rapid cosmetic improvement; the benefit is gradual and is one piece of a broader treatment plan that may include anti-androgens (spironolactone) and laser/electrolysis.
How PCOS-specific telehealth fits
Most compounded GLP-1 telehealth programs we review market primarily for weight management, not for PCOS-specific care. Patients with PCOS considering compounded GLP-1 should:
- Discuss the off-label nature of PCOS-specific treatment with their prescriber.
- Confirm contraception strategy if pregnancy is not desired.
- Maintain coordination with their gynecologist or endocrinologist for cycle and androgen monitoring.
- Plan for the possibility that ovulation may resume — practical consequences for relationships and family planning.
What about metformin and other PCOS therapies?
Metformin has been the standard insulin-sensitizing agent in PCOS for decades. Effect sizes on weight, cycle regularity, and ovulation are modest. GLP-1 receptor agonists appear meaningfully more effective on these endpoints, especially when weight is a contributing factor. Combination metformin + GLP-1 is common; consider this with the prescriber.